J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use

Johnson & Johnson (JNJ) announced that an FDA committee has unanimously recommended expanded use of its multiple myeloma drug Carvykti for earlier lines of treatment.J&J is looking for expansion of Carvykti’s label to include treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who are refractory to Bristol-Myers Squibb’s Revlimid (lenalidomide).The FDA’s O ...